Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

7.320 -0.490 (-6.27%)
Streaming Delayed Price Updated: 11:46 AM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gyre Therapeutics, Inc. - Common Stock

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million 
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS